These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 31392046)

  • 1. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets.
    Weinberg BA; Xiu J; Lindberg MR; Shields AF; Hwang JJ; Poorman K; Salem ME; Pishvaian MJ; Holcombe RF; Marshall JL; Morse MA
    J Gastrointest Oncol; 2019 Aug; 10(4):652-662. PubMed ID: 31392046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current biologics for treatment of biliary tract cancers.
    Zhao DY; Lim KH
    J Gastrointest Oncol; 2017 Jun; 8(3):430-440. PubMed ID: 28736630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
    Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
    JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell of origin in biliary tract cancers and clinical implications.
    Moeini A; Haber PK; Sia D
    JHEP Rep; 2021 Apr; 3(2):100226. PubMed ID: 33665585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS Allelic Variants in Biliary Tract Cancers.
    Moffat GT; Hu ZI; Meric-Bernstam F; Kong EK; Pavlick D; Ross JS; Murugesan K; Kwong L; De Armas AD; Korkut A; Javle M; Knox JJ
    JAMA Netw Open; 2024 May; 7(5):e249840. PubMed ID: 38709532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.
    Lowery MA; Ptashkin R; Jordan E; Berger MF; Zehir A; Capanu M; Kemeny NE; O'Reilly EM; El-Dika I; Jarnagin WR; Harding JJ; D'Angelica MI; Cercek A; Hechtman JF; Solit DB; Schultz N; Hyman DM; Klimstra DS; Saltz LB; Abou-Alfa GK
    Clin Cancer Res; 2018 Sep; 24(17):4154-4161. PubMed ID: 29848569
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular Analysis of Biliary Tract Cancers with the Custom 3' RACE-Based NGS Panel.
    Mitiushkina NV; Tiurin VI; Anuskina AA; Bordovskaya NA; Shestakova AD; Martianov AS; Bubnov MG; Shishkina AS; Semina MV; Romanko AA; Kuligina ES; Imyanitov EN
    Diagnostics (Basel); 2023 Oct; 13(20):. PubMed ID: 37891989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.
    Rizzato M; Brignola S; Munari G; Gatti M; Dadduzio V; Borga C; Bergamo F; Pellino A; Angerilli V; Mescoli C; Guido M; Rearden J; Gringeri E; Cillo U; Dei Tos AP; Zagonel V; Loupakis F; Lonardi S; Fassan M
    Eur J Cancer; 2022 May; 166():165-175. PubMed ID: 35303508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
    Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.
    Jain A; Kwong LN; Javle M
    Curr Treat Options Oncol; 2016 Nov; 17(11):58. PubMed ID: 27658789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA.
    Astier C; Ngo C; Colmet-Daage L; Marty V; Bawa O; Nicotra C; Ngo-Camus M; Italiano A; Massard C; Scoazec JY; Smolenschi C; Ducreux M; Hollebecque A; Postel-Vinay S
    Exp Hematol Oncol; 2024 Jan; 13(1):2. PubMed ID: 38191492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers.
    Mody K; Starr J; Saul M; Poorman K; Weinberg BA; Salem ME; VanderWalde A; Shields AF
    J Gastrointest Oncol; 2019 Dec; 10(6):1099-1109. PubMed ID: 31949927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway.
    Jacobi O; Ross JS; Goshen-Lago T; Haddad R; Moore A; Sulkes A; Brenner B; Ben-Aharon I
    Oncol Res Treat; 2021; 44(1-2):20-27. PubMed ID: 33279901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel insights into molecular and immune subtypes of biliary tract cancers.
    Bramel ER; Sia D
    Adv Cancer Res; 2022; 156():167-199. PubMed ID: 35961699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current options and future directions of systemic therapy for advanced biliary tract cancer.
    Prete MG; Cammarota A; D'Alessio A; Zanuso V; Rimassa L
    Explor Target Antitumor Ther; 2021; 2(5):416-433. PubMed ID: 36045701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer: Adding New Flavors to the Pizza.
    Queiroz MM; Lima NF; Biachi de Castria T
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers.
    Conci S; Catalano G; Roman D; Zecchetto C; Lucin E; De Bellis M; Tripepi M; Guglielmi A; Milella M; Ruzzenente A
    Int J Med Sci; 2023; 20(7):858-869. PubMed ID: 37324191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of ARID1A Expression Presents a Novel Pathway of Carcinogenesis in Biliary Carcinomas.
    Sasaki M; Nitta T; Sato Y; Nakanuma Y
    Am J Clin Pathol; 2016 Jun; 145(6):815-25. PubMed ID: 27334809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New developments in systemic therapy for advanced biliary tract cancer.
    Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
    Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.
    Simbolo M; Fassan M; Ruzzenente A; Mafficini A; Wood LD; Corbo V; Melisi D; Malleo G; Vicentini C; Malpeli G; Antonello D; Sperandio N; Capelli P; Tomezzoli A; Iacono C; Lawlor RT; Bassi C; Hruban RH; Guglielmi A; Tortora G; de Braud F; Scarpa A
    Oncotarget; 2014 May; 5(9):2839-52. PubMed ID: 24867389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.